WORLD HEALTH ORGANIZATION
AFRICAN PROGRAMME FOR ONCHOCERCIASIS CONTROL (APOC)

Nineteenth Session of the Joint Action Forum
Brazzaville, Congo, 11-13 December 2013

FINAL COMMUNIQUE

Opening of the Session & Election of officers

1. The nineteenth session of the Joint Action Forum (JAF) of the African Programme for Onchocerciasis Control (APOC) was hosted by the World Health Organization Regional Office for Africa (WHO/AFRO), from 11-13 December 2013 in Brazzaville, Congo. The meeting was attended by Honourable Ministers or their representatives of 16 onchocerciasis-endemic countries in Africa, 9 representatives of the donor community, the World Bank, the African Development Bank, WHO (Headquarters, AFRO, Country Office/Congo), senior health managers, Non-Governmental Development Organizations (NGDOs), the Mectizan Donation Programme, Merck & Co. Inc., Research Institutions, Directors and Coordinators of National Onchocerciasis Control Programmes, and Representatives of the Statutory Bodies of APOC. A complete list of participants is attached as Annex 1.

2. Welcoming and opening speeches were given by the APOC Director, Dr Jean-Baptiste Roungou; outgoing Chair of JAF18 and Minister of Public Health & AIDS Control, Burundi, Honourable Dr. Sabine Ntakarutimana; WHO Regional Director, represented by the Deputy Regional Director, Dr. M. Moeti, and the Minister of Health and Population of the Republic of Congo, Mr Francois Ibovi. On behalf of the President of the Republic of Congo, the Minister of Health and Population declared the meeting open.

3. The JAF elected the Minister of Health and Population, Republic of Congo, in the person of Mr. Francois Ibovi as Chair of JAF19, and the Chief Executive Officer, Sabin Vaccine Institute, in the person of Ambassador Michael Marine as Vice Chair. The Chair of JAF19 thanked the session for his election, and congratulated the outgoing Chair, Honourable Dr Sabine Ntakarutimana from Burundi for steering JAF in the past 12 months.

CSA Reflections

4. Dr Chris Mwikisa, Chair of the Committee of Sponsoring Agencies (CSA), presented the reflections of CSA to JAF. He recalled CSA’s guidance to APOC Management and contributions to the implementation of the decisions of JAF18 including the revision of the Concept Note and the Strategic Plan of Action and Budget, 2016-2025, as well as in setting up a Transitional Task Force that will provide technical advice during the transition of APOC to a new entity. The CSA Chair pointed out that the Committee had met three times in 2013 including two expanded meetings with participation of country representatives, donors and collaborating institutions) to review and finalize the revised Concept Note and the Strategic Plan and Budget 2016-2025 in line with the decisions of JAF18. He also mentioned...
that the budget is very indicative, and the Secretariat of APOC will work in 2014 with the countries and the development partners to determine current and projected external investments in the Neglected Tropical Diseases. These data will be used to develop a more precise implementation plan and budget for the elimination of onchocerciasis and LF from the countries during 2016 to 2025. On behalf of the CSA, he therefore recommended to the Forum to adopt the finalized documents.

**Progress on Elimination**

5. JAF received presentations on the WHO Progress report (1st September 2012 - 31st August 2013), the Technical Consultative Committee (TCC) activities including assessments of the elimination of onchocerciasis infection in Africa, as well as summaries of ivermectin treatments and trainings in 2012. Key highlights of the presentations included the treatment of over 100.79 million persons (76% therapeutic coverage) in over 181,000 communities (95% geographic coverage) of 24 countries; the training of 668094 community-directed distributors (CDDs) and 81520 health workers; as well as various activities conducted by APOC Management and the TCC. Updates were given on onchocerciasis mapping, delineation of ivermectin treatment boundaries and transmission zones, epidemiological and entomological evaluations. JAF was informed that based on outcomes of epidemiological evaluations of progress towards elimination all projects evaluated for Phase 1a in 2013 are making satisfactory progress and 5 projects in 4 countries evaluated for Phase 1b have met the criteria for stopping treatments.

6. Ministers of Health and heads of delegations from countries made statements that expressed their renewed efforts, achievements, challenges and way forward in the elimination of onchocerciasis and other neglected tropical diseases in their respective countries.

7. JAF commended APOC Management, TCC and the countries for well-articulated presentations. JAF accepted the WHO Progress report and expressed appreciation over the fact that some foci have met the epidemiological criteria for stopping treatments but noted that final decisions on stopping treatment will also take into account entomological results, prevalence levels in neighbouring projects and cross-border considerations.

8. JAF requested that in presenting treatment data, APOC Management should indicate the ultimate treatment goal including populations in the hypo-endemic areas where ivermectin treatment will be extended in the context of onchocerciasis elimination.

9. JAF recognized and attached considerable importance to capacity building as a way of improving treatment coverage. It therefore directed APOC Management to reflect, in future presentations on capacity building, training objectives and achievements for a clearer understanding of the capacity gaps, and to include former OCP countries in future capacity building plans.

**Strengthening Health Systems and Co-implementation**

10. There were presentations on the new momentum for Neglected Tropical Diseases (NTDs) and a summary of co-implementation within the NTD context. The presentation on the new momentum for
NTDs highlighted countries progress in developing and implementing NTD Master Plans based on strategic priorities identified by WHO/AFO. The summary on co-implementation reflected the provision of 49.4 million treatments/commodities for other 9 interventions alongside with ivermectin.

11. During discussions participants called for improved coordination among drug-donation pharmaceutical companies to ensure timely arrival in countries of all commodities for integrated implementation. They also called for better alignment and synergy of co-implementation with existing health systems, and timely reporting of NTD programme data.

12. The Forum acknowledged the efforts of countries and stakeholders for the successes recorded in co-implementing other interventions. JAF appreciated WHO’s efforts in improving coordination of drugs management and the development of a map that showed the overlap of onchocerciasis and lymphatic filariasis in the African region. JAF requested WHO/APOC to complete the map that further shows the overlap of loa loa in the onchocerciasis/lymphatic co-endemic areas to guide mass drug administration (MDA).

**Government contributions**

13. JAF received the report on the assessment of government contributions to efforts toward onchocerciasis elimination. The report highlighted the scope and coverage of resource estimation, onchocerciasis/NTDs expenditure classification schemes, methods and tools for estimating onchocerciasis and other NTD expenditures as well as the institutionalization of resource tracking systems at the country level.

14. Participants requested the presentation of contributions of various partners in graphic form that will be easier to follow and to understand trends over time, and emphasized the need to work closely with Ministers of Finance to improve funding for national NTD control/elimination programmes and to properly document government contributions.

15. JAF commended APOC and the CSA for undertaking this assessment and noted that understanding and tracking those government contributions strictly for onchocerciasis control/elimination could be difficult. JAF requested APOC to take forward the outcomes of the study by providing the methods, tools and preliminary results to countries to enhance their ability to collect and analyze their government contributions. JAF also asked APOC to collaborate with WHO National Health Account (NHA) teams so they incorporate NTD control activities in their routine reporting of health care expenditures in countries.

**Plan of Action and Budget, 2014-2015**

16. The revised Plan of Action and Budget 2014-2015 to intensify activities within the framework of strengthening onchocerciasis elimination efforts in the Africa Region indicated an adjustment of activities within budget of US$ 50.7 million already approved by JAF 18. JAF approved the adjusted activities in the revised PAB as presented. Participants also complimented APOC for introducing the results based management approach as well as the improved transparency in funds management. It
was noted that this budget however was not fully funded and adjustments might be needed. JAF expressed the need to have a final external evaluation of APOC with a comprehensive report to be presented at the JAF in December 2015.

The Future of APOC

17. JAF received the revised Concept Note and the revised Strategic Plan of Action and Indicative budget 2016-2025. The Concept Note proposed the establishment of a new regional entity to replace the current APOC from 2016 that will focus on lymphatic filariasis and onchocerciasis elimination but in the context of the wider NTD agenda. The Strategic Plan elaborated on the Concept Note and proposed a total indicative budget of US$ 813.9 million for the period 2016-2025, being the estimated cost to all partners for eliminating both diseases using different funding streams.

18. JAF applauded the wide consultations undertaken and the work done on these revisions and approved the documents and the budget as presented but, moving forward, called for additional information on the roles of the various organs proposed in the new entity.

19. JAF received a statement from Global Alliance to Eliminate lymphatic filariasis (GAELF) in support of the new entity. The global lymphatic filariasis community (as represented by GAELF) urges:

   a. Full and equal partnership between both lymphatic filariasis and onchocerciasis communities together with endemic African countries suffering either disease to move the elimination agenda forward.
   b. Prompt establishment of an independent joint technical oversight committee to prioritize the necessary strategies for increased up scaling of the interventions and the introduction of new strategies where appropriate and prior to APOCs closure at the end of 2015.
   c. Rapid integrated mapping of both diseases.
   d. Assessment and rationalization overlap of implementation and or/evaluation units for both diseases.
   e. Scale up of programme implementation in the areas access to medicine remains limited.
   f. Prompt introduction of the new WHO recommendations for interventions in Loa loa endemic areas, linking vector control for lymphatic filariasis with malaria control programmes using long lasting insecticidal nets.
   g. Acceleration of the use of twice yearly treatments of ivermectin in Africa to interrupt onchocerciasis and possibly lymphatic filariasis transmission where appropriate.
   h. Expansion of WHO morbidity management strategies for lymphatic filariasis as outlined in the new programme managers guide.

Closed Door Session

20. The Strategic Plan of Action identified five specific areas in which rapid progress has to be made if the new entity is to start “at speed” at the beginning of 2016. These five topics are:
a. Accelerating and completing scale up of MDA for lymphatic filariasis and onchocerciasis (noting that all areas should have been mapped and started treatment by the end of 2015 to meet elimination targets).

b. Mapping, planning and mobilising resources to implement the plan (including resources needed to bridge the funding gap in 2014 and 2015). This will also include the development of a detailed budget for the new entity.

c. Designing new inclusive governance mechanisms and ensuring that the Memorandum of Understanding (MoU) documents and Trust Fund documents are revised and ready to serve the needs of the new entity.

d. Ensuring that management and institutional structures are reformed to suit the purpose of the new entity.

e. Ensuring that progress is made on critical technical issues essential for accelerated progress towards elimination of onchocerciasis and lymphatic filariasis.

21. These five areas were taken as discussion topics for the closed session to get recommendations.

22. The group of Ministers of Health of African countries in their statement after the closed session highlighted the following:

a. Human resources need to be strengthened at districts level. Additionally, health development committees and health center management committees should be strengthened.

b. Ministers and country delegates reiterate their commitment to strengthen government leadership and improve coordination of partners and interventions at country level. They also commit to mobilizing funds for NTD research and surveillance as well as to strengthening community empowerment for NTD Programmes.

c. The Ministers and country representatives express their commitment to reinforce NTD structures and avoid duplication and waste of funds. They also commit to deploy funds from central/strategic level to operational level in the country.

d. Countries need to be represented in the extended CSA.

23. The Donors after the review of the issues stated as follows:

a. The Donors’ group welcomed and endorsed the GAELF statement that supports the establishment of a new entity that focuses on onchocerciasis and lymphatic filariasis, and the group looks forward to these communities working together as equal partners.

b. Given the support from the Bill & Melinda Gates Foundation (BMGF) and other partners, mapping for all NTDs should be completed in the African region by end of 2015.

c. APOC is encouraged to manage available funds and is advised to be prudent in its expenditure especially for 2014, since it is unlikely that donors will be committing additional funds in the short term. However, progress in resolving outstanding issues may contribute to unlocking more funding which will help leverage funds which should help ensure onchocerciasis targets are met.
Though funding may be constricted in 2014, APOC should continue co-implementation to keep donor confidence. The group notes that significant funds will be needed for LF program scale up and this number needs to be quantified. APOC Management should work with partners (the World Bank, Global Network for NTD (GNNTD)) to prepare a resource mobilization plan. The group suggests organizing a donor replenishment forum in 2015.

d. The proposed governance working group to be set up in 2014 is a welcome development and the group looks forward to being consulted as it deliberates.

e. The donor group welcomes the plan for APOC to undertake an independent management review. The group recommends that the TOR for the review is subjected to final confirmation by the CSA. The existing institutional structures should be reviewed to build on strengths and correct weakness. For example, the CSA should include country representations. The TCC needs to be reinforced with representation from LF as well as onchocerciasis communities. A review of the strengths and weaknesses of JAF could contribute to the design of the Partners forum. The strength of JAF is a high level of government representation. The group notes that this level of representation is equally relevant to the LF and broader NTD agenda.

f. The group recommends additional efforts to engage with finance ministers. It is proposed that existing AFRO representation at the Harmonization of Health in Africa (HHA) Forum could be used to introduce the NTD agenda.

g. The increasing gender mainstreaming in APOC operations is noted and welcomed. An important omission is an emphasis on inclusion ensuring the people with disabilities are fully included in the programs.

h. It is important that the respective roles and responsibilities of WHO/AFRO and APOC are defined. A diagram would be useful.

24. On its own part the NGDO group proposed the followings:

a) Accelerating scale up of LF and onchocerciasis:

i. The new support by the Bill & Melinda Gates Foundation for more rapid completion of mapping is a new strength for completing this greatly needed task. However there is a need for better coordination and clear information on other groups engaged in mapping NTDs. There is need for inclusiveness, guidelines and transparency in this area, especially related to who is funding what mapping activities.

ii. There is a need to use the strength of APOC with the WHO banner to get access and influence in countries. This is essential to facilitate effective scaling up MDA for LF and onchocerciasis in countries.
iii. National capacity needs to be strengthened. In many countries, there is an inability to absorb additional funds that are currently available.

iv. Treatment in urban areas remains a challenge and this needs to be given consideration within the context of accelerating scale up of MDA.

b) Mapping, planning and mobilizing resources

i. There are few donors at the table to expect LF full scale up in Africa by 2016. Efforts should be made as soon as possible to mobilize new donors, and an important opportunity to do so may be at the 2014 London Declaration follow up meeting. Pairing of donors with countries is a mechanism that should be considered.

c) Governance mechanism

i. NGDOs should have a seat in both the technical and executive committee, as well as the larger partner’s forum in the current governance scheme briefly outlined in the ‘new entity’ documents.

ii. Governance should have a much more extensive partnership composition than currently seen in APOC.

iii. NGDOs need to re-examine their own relationships between currently separate oncho and LF NGDO groups to speak with a common voice on these committees.

d) Management

i. The new entity should build and encourage country ownership and technical empowerment (national technical committees). The new program should be ‘bottom up,’ not ‘top down’.

ii. The new entity needs to put in place a new more agile financial system that allows better transfer of funds.

iii. A review should be made of the best location for the new entity that can easily be accessed, especially from the African countries.

iv. An independent management review is encouraged now to generate new ideas for the pre 2016 scale up. However, the management review for the new entity will be impossible to conduct until the governance structure, location of the entity, and magnitude of the tasks it will undertake have been more clearly determined.

e) Technical issues essential for accelerated progress towards elimination

i. The Group strongly agrees with the GAELF recommendation read to JAF that there is need to have a new and independent technical and programmatic committee immediately, for 2014-2015, that will include a broader representation different from TCC. The TCC should phase out with the end of APOC in 2015.

ii. Technical issues related to elimination of both LF and onchocerciasis will be tackled by the new technical committee, and will relate to current WHO guidelines.

iii. The meeting budget line in the current APOC budget should be used to support the meetings of the new committee.

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
25. Clarifying the relationship that will exist between WHO and the new entity (PENDA), the WHO Regional Director informed JAF that:

a. WHO is open and flexible to adapt with the recommendation of JAF on the future of APOC.
b. Some of the core functions of WHO will be delegated to the new entity to ensure that it supports the entire 47 countries in the African region to implement an integrated onchocerciasis and LF programme.
c. The new entity will keep the same autonomy as APOC provided donors decide on an appropriate model of funding that sustains APOC gains and expands to LF and where possible other PCT NTDs.
d. Learning from the experience of APOC, the CSA, TCC and JAF will need to have their mandates revised and membership expanded to reflect the new focus on onchocerciasis and LF integrated programme implementation as well as taking into consideration the overall NTD action plan.
e. The roles and responsibilities of WHO HQs and AFRO are clearly defined in the 12th General Programme of Work of WHO.

26. JAF expressed its appreciation to the APOC constituent groups and to the WHO Regional Director for the suggestions, thoughts and clarifications and urged that they should be seriously considered in implementing the Strategic Plan.

Partnership

27. The report of the NNN and the NGDO Coordination Group for Onchocerciasis Elimination was presented to the session. The NGDO Group highlighted the renaming of the Group as “NGDO Coordination Group for Onchocerciasis Elimination” and the Group’s continued managerial, technical and financial support to onchocerciasis control and elimination activities in 30 out of 38 onchocerciasis endemic countries worldwide. The Group further highlighted that other NGDO coordination groups have successfully advocated for increased funding for trachoma mapping and have increased awareness of LF morbidity management and disability prevention (MMDP) as well as the involvement of other sectorial partners such as WaterAid and International Leprosy Elimination Programme (ILEP) in the newly formed NTD consortium.

28. The Group noted the achievement of 100 million assisted treatments in 2012, and provision of US $7 million in support to African programs in 2012 and over US $44 million between 2007-2012. JAF was updated on the elimination program in the Americas (OEPA). It was informed of the ceremony of the verification by WHO of the elimination of onchocerciasis from Colombia, and the request from Ecuador for a WHO team for verification of elimination in that country. Both countries have used a twice per year ivermectin treatment strategy. It was recommended that JAF monitor progress towards implementing a twice per year strategy in parts of the African region. The Group noted the importance of the year 2020 in the London Declaration on NTDs and in WHO Geneva and AFRO plans. The Group strongly recommended to JAF that APOC articulate clear 2020 goals for onchocerciasis, in alignment with the importance of 2020 achievements. NGDOs would expect to continue to play a key role in the governance structures in the new entity to be launched in 2016.
29. The JAF acknowledged the continued significant contribution of NGDOs to the elimination of onchocerciasis and other neglected tropical diseases.

Programme Management and Finance

30. The audit report and a presentation on financing of APOC were presented to JAF. The World Bank, as the fiscal agent, presented APOC’s receipts and pledges to-date amounting to $268 million and noted that although the revised plan during the interim period, 2014 and 2015, was endorsed by the JAF18, it attracted limited funding from donors. This resulted in insufficient funds to cover the revised budget resulting in a projected shortfall of $22 million. The World Bank welcomed the Arab Bank for Economic Development in Africa (BADEA) as a new development partner. The World Bank made the following recommendations: a) to closely monitor APOC’s expenditures and income in real time and to modify the budget accordingly; b) to aim for sustained treatment in 2014; and c) to plan for scale up in 2015. The World Bank closed with the following next steps: a) to work with partners to develop consensus around funding needs for a new regional entity; b) to continue to seek interim funding; and c) to plan for a major Replenishment Forum in 2015.

31. Representatives of the various donors at the meeting made statements on their support for APOC. Such statements were received from ADB, BADEA, BMGF, Canada, Merck & Co, NGDO Coalition, Nigeria, Saudi Fund, Sightsavers, USAID and World Bank.

32. The Forum took note of the Auditor’s report. JAF thanked the donors and NGDO Partners for their renewed commitment and support.

Research

33. JAF received presentations on LF and onchocerciasis related research and modelling supported by the Bill & Melinda Gates Foundation. The Foundation has many investments in a diverse set of projects to address challenges to the programs and to help ensure success. These projects include Death to Onchocerciasis and LF (DOLF), AWOL, Shrinking the Map, as well as Test and Treat for overcoming Loa loa barrier to programs. Additional investments are Black Fly Trap development, Coalition for Operational Research on NTD (COR-NTD) Filling the Gaps, Onchocerciasis elimination criteria, Ov16 diagnostic development, modelling of NTD program impact, Funding Gap Analysis, and Grand Challenges Explorations which is a portfolio of multiple grants of 100,000 USD each for paradigm shifting ideas that could move forward programs around LF and onchocerciasis.

34. JAF also received presentations on macrofilaricidal drug development program/field research to support LF and Oncho Elimination Programmes, modelling and mapping and further needs. The anti-Wolbachia therapy delivers safe macrofilaricidal and sterilising activity leading to a progressive and sustained elimination of macro/microfilarial load, thus avoiding the risk of adverse events from target species and those due to co-infections with Loa loa. The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project presented preliminary results of a community trial conducted in the Republic of Congo as part of the DOLF project. This 3-year trial aims at evaluating the effects of biannual mass treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminthiases. The
Modelling project looks at the current burden of disease and to what extent it can be reduced when the WHO targets in the London declaration are met.

35. The session commended the presenters and acknowledged the significant contributions the product of these activities have made and will make in ensuring the achievement of LF and onchocerciasis elimination. JAF expressed the hope that the modelling outcomes will help bring in more precision on end-dates for elimination. JAF also acknowledged the vital issues and progress made in the development of products and tools that could fast-track the process of elimination of LF and onchocerciasis in the African region.

Date and Place of the 20th JAF session

36. The 20th session of JAF will be held in the second week of December 2014. The venue will be communicated at a later date after further consultation by APOC Management with the Chair of JAF19 and the Chair of the CSA.

Closure

37. JAF thanked the World Health Organization Regional Office for Africa (WHO/AFRO) for hosting JAF19 and the government of the Republic of Congo for the warm hospitality.
Annex 1

African Programme for Onchocerciasis Control (APOC)
Programme africain de lutte contre l'onchocercose

JOINT ACTION FORUM
Office of the Chairman

JAF-FAC
FORUM D’ACTION COMMUNE
Bureau du Président

JOINT ACTION FORUM
Nineteenth session
Brazzaville, Congo, 11-13 December 2013

LIST OF PARTICIPANTS/LISTE DES PARTICIPANTS

APOC COUNTRIES/PAYS APOC

Burkina Faso

01. Dr Isaïe MEDAH, Directeur de la Lutte contre la Maladie, Ministère de la Santé, 03 BP 7009, Ouagadougou 03, Burkina Faso – Tel: +226 70 25 57 13/78 31 22 13 - E-mail: isaiemedah@yahoo.fr; alexandracath@gmail.com

Burundi

02. Dr Sabine NTAKARUTIMANA, Ministre de la Santé Publique et de la lutte contre le Sida, Ministère de la Santé Publique et de la lutte contre le SIDA, BP 1820, Bujumbura, Burundi – Tel: +25722229195 – Fax: +257222229196 – E-mail: ntakarutimana2006@yahoo.fr

03. Dr Onésime NDAYISHIMIYE, Directeur du Programme National Intégré de lutte contre les Maladies Tropicales Négligées et la Cécité (PNIMTC), Ministère de la Santé Publique et de la lutte contre le SIDA, BP 3128, Bujumbura II, Burundi – Tel: +25779910036 ; + 25722249333 ; +25722257153; +25722249333 – Mobile: +25777735102 – Fax: +25722229196 - E-mail: ndayones@yahoo.fr

04. Dr Dieudonné NICAYENZI, Directeur Général de la Planification, Ministère de la Santé Publique et de la lutte contre le Sida, BP 1820, Bujumbura, Burundi – Tel: +25722229195; +25771456813; +25777737480 – Fax: +25722229196 – E-mail: nidieu24@yahoo.fr

05. Madame Yvette GATEYINEZA, Conseillère au Cabinet du Ministre (Chargée de la Communication), Ministère de la Santé Publique et de la lutte contre le SIDA, BP 1820, Bujumbura, Burundi – Tel: +25779963451 – Fax: +25722229196 – E-mail: yvettegates@yahoo.fr

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
Cameroon/Cameroun

06. Son Excellence Monsieur NJIMOLUH KOMIDOR, Ambassadeur de la République du Cameroun au Congo

07. Dr Alain Georges ETOUNDI MBALLA, Directeur de la lutte contre la Maladie, les Epidémies et les Pandémies, Président du GTNO, Ministère de la Santé Publique, BP 155, Yaoundé, Cameroun - Tel : +237 77 70 21 67 - Email : dretoundi@yahoo.fr

08. Dr Benjamin Didier BIHOLONG, Coordonnateur du Programme National de Lutte contre l’Onchocercose, Secrétaire Exécutif du GTNO s/c OMS, BP 155, Yaoundé, Cameroun – Tél: Portable: +237 99 61 28 00 – Fax: +237 22 22 44 19 – E-mail: biholong_di@yahoo.fr

Chad

09. Dr Mahamat Annour WADAK, Secrétaire Général du Ministère de la Santé Publique, BP 440 N’Djamena, Tchad – Tél : +235 66 26 07 87 – E-mail: wadakourak@yahoo.fr

10. Monsieur Nadjilar LOKEMLA, Coordonnateur du Programme National de Lutte contre l’Onchocercose (PNLO), Ministère de la Santé Publique, B.P. 4057, N’Djamena, Tchad – Tel: +235 66 29 01 64 – Fax : +235 22 52 48 38 – E-mail: nadjilar@yahoo.fr

Congo

11. Mr François IBOVI, Ministre de la Santé et de la Population, Ministère de la Santé et de la Population, BP 2101 Brazzaville, République du Congo

12. Mr Jean Philippe NGAKOSSO, Directeur de Cabinet, Ministère de la Santé et de la Population, BP 2101 Brazzaville, République du Congo

13. Dr Damase BODZONGO, Conseiller Sanitaire et au Bien Etre, Ministère de la Santé et de la Population, BP 1066 Brazzaville, République du Congo – Tél : 00 242 05 536 42 77 – E-mail: bodzongo_damase@yahoo.fr

14. Mr Roger Emmanuel OBA, Conseiller à la Coopération – Tél : 00242 05 547 23 28 – E-mail: rogeraba2006@yahoo.fr

15. Mr Patrice ONDONGO, Conseiller en Communication, Brazzaville, République du Congo

16. Mr Florent BALANDAMIO, Conseiller à la population du Ministre, Brazzaville, Congo – Tel : 06 669 02 63 – E-mail : florentbalandamio@yahoo.fr

17. Professeur Alexis ELIRA DOKEKIAS, Directeur Général de la Santé, B.P. 78, Brazzaville, Congo, Tél : (242) 81 57 46; Fax : (242) 81 04 81, E-mail: dgsante@yahoo.fr; dokekias@yahoo.fr

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
18. Prof. OBENGUI, Directeur de l’Épidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, BP 1066 Brazzaville, République du Congo – Tél : 00 242 556 35 44 – E-mail: obengu52@ymail.com

19. Dr François MISSAMOU, Médecin Chef du Programme National de Lutte contre l’Onchocercose, Ministère de la Santé et de la Population, BP 1066 Brazzaville, République du Congo – Tél : 00242 552 549 41 / 00242 66 680 563 – E-mail: missamou_fran@yahoo.com ; francmissamou2000@gmail.com

20. Mr José Rony ABOULASSAMBO, Collaborateur, Brazzaville, République du Congo

21. Mrs Marlyce TCHIBINDA, Journaliste Reporter, Brazzaville, République du Congo - Tél : 06 669 38 14 / 04 418 28 38 – E-mail : laurianembt@gmail.com ; ntcibindabatchi@yahoo.com

Côte d’Ivoire

22. Prof. Yapo Félix BOA, Directeur Général de la Santé, Ministère de la Santé et de la lutte contre le SIDA, 13ème étage de la Cité Administrative Tour C, Abidjan – Tél : +225 20 21 72 09 – Mobile : +225 07 09 64 94 – E-mail: boa.felix@gmail.com

23. Dr Amenan Marie Madeleine KOUKOU EPSE ILUNGA, Directeur/Coordonnateur du Programme National de la Santé oculaire et de la Lutte contre l’Onchocercose (PNSO-LO), 25 BP 299 Abidjan 25, Côte d’Ivoire – Tél: +225 22.44.37.83 – Mobile : +225 07 08 38 03 - Fax: +225 22.44.37.83 – E-mail: magdy_koua@yahoo.fr

Democratic Republic of the Congo/République Démocratique du Congo

24. Dr Marcel MUKENGESHAYI KUPA, Secrétaire Général à la Santé a.i., 39, Avenue de la Justice, C/Gombe, Kinshasa, République Démocratique du Congo – Tel: +243 99 99 47 138 – E-mail: mukkupa@yahoo.fr

25. Dr Benoit KEBELA ILUNGA, Directeur de la Lutte contre la Maladie, 39, Avenue de la Justice, C/Gombe, Kinshasa, République Démocratique du Congo – Cellulaire: +243 99 99 72 691 – E-mail: kebelailunga@gmail.com

26. Dr Pitchouna AWACA UVON, Directeur du Programme National de Lutte contre l’Onchocercose, 36, Avenue de la Justice, C/Gombe, Kinshasa, République Démocratique du Congo – Cellulaire: +243.81.78.22.566 – E-mail: pnlo_rdc@yahoo.fr; naopitchouna@yahoo.fr

Ghana

27. Dr Benjamin Aboagye MARFO, Deputy Program Manager – Ghana, NDT, Ghana Health Services, Neglected Tropical Diseases Programme, Accra – Tel: +233 054 873 8744 – E-mail: marfobenjamin2002@yahoo.com
Guinea/Guinée

28. Dr André GOEPOGUI, Coordonnateur, Programme National de Lutte contre l’Onchocercose et la Cécité/MTN, Ministère de la Santé et de l’Hygiène Publique, BP 585, Conakry, République Guinée – Tel: +224 68 51 80 63 – E-mail: agoep@yahoo.fr

Liberia

29. Mr Chea Sanford WESSEH, Assistant Minister for Statistics, Ministry of Health & Social Welfare, P.O. Box 10-9009, 1000 Monrovia 10, Liberia, West Africa – Tel: +231 88 65 38 603 – E-mail: cswesseh@yahoo.com

30. Mr Anthony Kerkula BETTÉE, Physician Assistant and National Onchocerciasis Coordinator, Neglected Tropical Diseases Program, Ministry of Health & Social Welfare, P.O. Box 10-9009, 1000 Monrovia 10, Liberia, West Africa – Tel: +231 88 65 39 548 – E-mail: tbettee@yahoo.com

Mali

31. Dr Mamadou Oumar TRAORE, Coordonnateur du Programme National de Lutte contre l’Onchocercose (PNLO), Direction Nationale de la Santé, B.P. 233, Bamako, Mali – Tél: +223 66 71 17 66; +223 20 22 64 97 – Fax : +233 20 22 36 74 - E-mail: traoremot@yahoo.fr

Niger

32. Mr. Alzouma Dari ISSIFI, Directeur de Cabinet, Ministère de la Santé Publique, BP 623 Niamey, Niger – Tel: +227 96 29 41 19 / +227 90 48 83 17 – Fax : +227 20 35 03 46 – E-mail: dalzouma@yahoo.com

33. Dr Abdoul-Azize KAINÉ, Directeur Général de la Santé Publique, Ministère de la Santé Publique, BP 623, Niamey, Niger – Tel: +227 97 96 11 22 – Fax : +227 20 35 03 46 – E-mail: kainabdul@yahoo.fr

34. Dr Salissou ADAMOU, Coordonnateur Programme Onchocercose et Filariose Lymphatique, Programme National d’Elimination de l’Onchocercose et de la Filariose Lymphatique, Niamey, Niger – Tel: +227 96 96 03 76 – Fax : +227 20 35 03 46 – Email: sadamouba@yahoo.fr

Nigeria

35. Dr Bridget OKOEGUAL, Director Public Health, Department of Public Health, Federal Secretariat, Federal Ministry of Health, Abuja, Nigeria – Tel: +234 (0) 8037211528 – E-mail: bridgeclinic2002@yahoo.com
36. Dr Yisa Adewale SAKA, Federal Ministry of Health, Federal Secretariat, Phase III, 9th Floor, Room 909, 9th Floor, Abuja – Tel: +234 803 302 93 87 – E-mail: yisaasaka@yahoo.com

Tanzania

37. Dr. Seif S. Rashid (MP) - Deputy Minister for Health, Ministry of Health & Social Welfare, P.O. Box 9083, Dar-es-Salaam, Tanzania – Tel: +255 22 21 12 883 – Fax: +255 22 21 37 759 – Email: depminhealth@gmail.com

38. Dr Upendo John MWINGIRA, Program Manager, Ministry of Health & Social Welfare, P.O. Box 9083, Dar-es-Salaam – Tel: +255 713 262 865 – Fax: +255 222 121 360 – E-mail: umwingira@yahoo.com

Togo

39. Dr Koku Sika DOGBE, Directeur Général de la Santé, Ministère de la Santé, BP 336, Lomé, Togo – Tel: +228 22 21 09 27 – Cellulaire: +228 90 95 52 65 – Fax: +228 22 21 89 48 – E-mail: dogbekokou17@hotmail.fr

40. Dr Koffi Potchoziou KARABOU, Coordonnateur du Programme National de Lutte contre l’Onchocercose, BP 487, DRS/Kara, Togo – Tél : +228 90 02 47 95 / +228 26 60 17 10 – E-mail: karaboup@yahoo.fr

Uganda/Ouganda

41. Dr Elioda TUMWESIGYE, Minister of State for Health (General Duties), Ministry of Health, P.O. Box 7272, Plot 6, Lourdel Road, Nakasero, Kampala, Uganda – Tel: +256-414-34087 – E-mail: elioda@health.go.ug

42. Dr Alex OPIO, Ag. Commissioner Health Services, National Disease Control, Ministry of Health, P.O. Box 7272, Plot 6, Lourdel Road, Nakasero, Kampala, Uganda – E-mail: opioalex@infocom.co.ug

DONORS/DONATEURS

African Development Bank/Banque Africaine de Développement

43. Dr Maïmouna DIOP LY, Physician/Principal Health Analyst, African Development Bank (AfDB), Principal Health Analyst, Human Development Department (OSHD), Health Division, African Development Bank Group, Avenue Joseph Anoma - BP 01 1387, Abidjan-Côte d’Ivoire - Tel Office: +225 20 20 42 11 - Mobile: +225 77 22 79 29 - E-Mail: m.diolly@afdb.org
Arab Bank for Economic Development in Africa (BADEA)

44. Mr Mohamed EL AICHOUNI, Head, Technical Assistance Division, Abdel-Rahman El-Mahdi Street, P.O. Box: 2640, Khartoum 11111, Republic of Sudan – Tel: +249-922 11 44 62; +249-183-773709/773646 – Fax: +249-183-770600/770498 – Email: elaichouni2000@yahoo.fr; badea@badea.org

CIDA/Canada

45. Dr Pierre-Claver BIGIRIMANA, Senior Health Specialist, Thematic and Sectoral Specialists Division, Global Issues and Development Branch, Foreign Affairs, Trade and Development Canada, 200, promenade du Portage, Gatineau (Québec)/Canada K1A 0G4, 8th floor (8-045) – Tel: +1 819-934-5618 – Fax: +1 819 994-1208 – Email: pierre.bigirimana@international.gc.ca

France

46. Dr Jean Pierre LAMARQUE, Conseiller régional de coopération en santé pour le Congo, le Congo Démocratique, le Gabon et l’Angola, Ambassade de France à Brazzaville, BP 2089 SCAC – Brazzaville, Congo – Tel Mobile : + 242 06 882 28 77- Bureau : + 242 05361 24 06 /07/08/09 – France : 06 75 33 49 21 - E-mail: jean-pierre.lamarque@diplomatie.gouv.fr

Merck/MSD

47. Ms Janet VESSOTSKIE, Director, Corporate Responsibility, Merck, One Merck Drive WS2A-56, P.O. Box 100, Whitehouse Station NJ 08889-0100, USA – Tel: +908 423 6441 Fax: +908 735 1839 – Email: janet.vessotskie@merck.com

Sabin Vaccine Institute

48. Mr Michael MARINE, Chief Executive Officer, Sabin Vaccine Institute, 2000 Pennsylvania Avenue, NW Suite 7100, Washington DC 20006, USA – Tel: +1.202-842-5025 – Fax: +1.202-842-7689 – Email: kalin.perkov@sabin.org

Sightsavers

49. Dr Caroline Harper, Chief Executive Officer, Sightsavers, Grosvenor Hall, Bolnore Road, Haywards Heath, West Sussex, RH16 4BX, United Kingdom – Tel: +44 1 444 446 600 – Fax: +44 1444 446 688 – E-mail: charper@sightsavers.org

50. Mr. Simon BUSH, Director, Neglected Tropical Diseases (NTDs), Sightsavers, 21 NII Nortei Ababio Street, Airport Res. Area, Accra, Ghana – Tel: +233 302 774 210; +233 748 702 – Fax: +233 302 780 227 – Email: sbush@sightsavers.org

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
The Saudi Fund for Development

51. H. E. Eng. Hasan ALATTAS, Director General, Technical Department, The Saudi Fund for Development, P.O. Box 1887, Riyadh 11441, Saudi Arabia – Tel: +966-505482724 – Fax: +966-11-464-0292 – Email: abamaan@yahoo.com; hatas@sfd.gov.sa

52. Mr Saud A. AL-FANTOUKH, Director General Audit & Control Department, The Saudi Fund for Development, P.O. Box 50483, Riyadh 11523, Kingdom of Saudi Arabia – Tel: +966 11 279 41 41 – Fax: +966-11 464 74 50 – Email: salfantoukh@gmail.com

53. Mr Ibrahim AL SUGAIR, Chief Economist, The Saudi Fund for Development, P.O. Box 1887, Riyadh 11441, Saudi Arabia – Tel: +966-50 524 04 47 – Fax: +966-11 464 74 50 – Email: isugair@sfd.gov.sa

The World Bank/Banque Mondiale

54. Dr Donald A.P. BUNDY, Lead Health and Education Specialist and APOC Coordinator, Africa Region Human Development Department, The World Bank, 1818 H Street NW, Room J10 – 131, Washington DC 20433, USA – Tel: +1.202 473-3636 – Email: dbundy@worldbank.org

55. Dr Andy Chi TEMBON, Senior Health Specialist, African Region Human Development Department, The World Bank, 1818 H Street, NW, Room J10 – 142, Washington DC 20433, USA – Tel: +1.202-473-4879 – Email: atembon@worldbank.org


NGDOs/ONGD

Carter Center

57. Dr Frank Oliver RICHARDS, MD, Director, River Blindness Elimination and LF Elimination Programs, The Carter Center, 453 Freedom Parkway, Atlanta, GA 30307, USA – Tel: +1.404 420 3898 – Fax: +1 404 420 3881 – Email: frich01@emory.edu

Charitable Society for Social Welfare (CSSW)

58. Mr Isameldin Awad Elhussien SALAH, NTDs Program Director, Charitable Society for Social Welfare (CSSW) – Tel: 00967-733843349 - Fax: 00967-1-464390 - E-mail: info@csswyemen.org; artols2002@yahoo.com
Christoffel Blindenmission (CBM)

59. Dr. Muhammad Babar QURESHI, Director Neglected Tropical Diseases (NTDs), 7-8, Oakington Business Park, Cambridge, CB24 3DQ, United Kingdom - Tel: +44 1223 484700 – Mobile: +44 7872 201317 - Fax: +44 1223 484701 – E-mail: babarq@cbmuk.org.uk; mbqureshi1@gmail.com

IMA World Health

60. Ms. Ann VARGHESE, Senior Program Officer, IMA World Health, 500 Main Street, P.O. Box 429, New Windsor, MD 21776, USA – Tel: +1-410-635-8716 – Fax: +1.410-635-8726 – E-mail: annvarghese@imaworldhealth.org

61. Ms. Susan DUBERSTEIN, Senior Technical Director Programs, 1730 M Street, NW, Suite 809, Washington, DC 20036 – Tel (Direct): 443-547-8527 ; (Office): 877-241-7952 – E-mail: SusanDuberstein@imaworldhealth.org

International Agency for the Prevention of Blindness (IAPB)

62. Mr. Peter ACKLAND, Chief Executive Officer, International Agency for the Prevention of Blindness (IAPB), LSHTM, Keppel Street, London WC1E 7HT, United Kingdom – Tel: 0044 207 927 2969 – Mobile: 0044 773 878 5300 – E-mail: packland@iapb.org

Mectizan® Donation Program

63. Dr Adrian Dennis HOPKINS, Director, Mectizan® Donation Program (MDP), 325 Swanton Way, Decatur, GA- 30030, USA – Tel +1 404-371-1460 – Fax: +1.404-371-1138 – Email: ahopkins@taskforce.org

64. Dr Kisito OGOUSSAN, Associate Director (Onchocerciasis), Mectizan® Donation Program (MDP), 325 Swanton Way, Decatur, GA- 30030, USA – Tel +1.404-687-5633 – Fax: +1.404-371-1138 – Email: kogoussan@taskforce.org

Organisation pour la Prévention de la Cécité (OPC)

65. Dr Bernard PHILIPPON, Secrétaire Général de l’OPC, 17 Villa d’Alésia, 75014 Paris – France – Tel: 331 44 12 41 90 ; 331 40 44 94 04 - Fax: +331 44 12 23 01 – E-mail: abphilippon@yahoo.fr

United Front Against Riverblindness (UFAR)

66. Dr Daniel Luhata SHUNGU, Executive Director, United Front Against Riverblindness (UFAR), 13 Carnation Place, Lawrenceville, New Jersey 08648, USA – Tel: +1.609-771-3664 – Mobile: +1.609-954-3398 – E-mail: dishungu@aol.com
OTHER PARTNERS/AUTRES PARTENAIRES

AWOL/Liverpool School of Tropical Medicine

67. Prof. Mark TAYLOR, Head of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, United Kingdom – Tel: +441517052564 – Fax: +441517053371 – E-mail: mark.taylor@liv.ac.uk

Bill & Melinda Gates Foundation

68. Dr Julie JACOBSON, Senior Program Officer, Bill & Melinda Gates Foundation, P.O. Box 23350, Seattle, WA 98102 USA – Tel: +206-770-1672 - E-mail: Julie.Jacobson@gatesfoundation.org ; Meredith.russell@gatesfoundation.org

69. Mr Aryc W. MOSHER, Program Officer, Bill & Melinda Gates Foundation, P.O. Box 23350 Seattle, WA 98102 USA – Tel: +206-770-2461 - E-mail: aryc.mosher@gatesfoundation.org

CDC Atlanta

70. Dr Christine DUBRAY, Medical Epidemiologist, Parasitic Diseases Branch of CDC, 1600 Clifton Road, NE, Mailstop A-06, Atlanta, Georgia, 30333, USA – Tel: +1-404-718-4769 – Fax: +1-404-718-4816 - E-mail: ffg5@cdc.gov

71. Dr Paul CANTEY, Medical Epidemiologist, Parasitic Diseases Branch of CDC, 1600 Clifton Road, NE, Mailstop A-06, Atlanta, Georgia, 30333, USA – Tel: +1-404-718-4735 – Fax: +1-404-718-4816 - E-mail: gdn9@cdc.gov

Center for Neglected Tropical Diseases Liverpool School of Tropical Medicine, United Kingdom

72. Prof. Moses BOCKARIE, Director, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, Merseyside, United Kingdom – Tel: +44 151 705 3335 – E-mail: moses.bockarie@liv.ac.uk

73. Mrs Joan FAHY, Project Manager, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, United Kingdom – Tel: +44 151 705 3145; Mobile:+44 788 072 2087 – E-mail: fahy@liv.ac.uk

DOLF Project

74. Dr Gary J. WEIL, Professor, Washington University School of Medicine, 660 S. Euclid Ave, Box 8051 St. Louis, MO 63110 USA – Tel: +1 314 747 5198 – Fax: +1 314 454 5293 – E-mail: gweil@dom.wustl.edu
ERASMUS

75. Dr Wilma A. STOLK, Senior Researcher/Epidemiologist, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands, Tel: +31 10 704 3730 (Dir) / 703 8460 (Secr) – Fax: +31 10 703 8474 - E-mail: w.stolk@erasmusmc.nl

Family Health International (FHI360)/End in Africa

76. Dr Joseph Brima KOROMA, Technical Advisor, END Neglected Tropical Diseases in Africa Project, 2nd Floor Marvel House, 148A Giffard Road, P.O. Box CT4033, Cantonments, Accra, Ghana, – Tel: +233 302 740780 Ext: 75156 – Fax: +233 302 782174 – E-mail: JKoroma@fhi360.org

Institut de Recherche pour le Développement (IRD)

77. Dr Michel BOUSSINESQ, UMI-233, Centre IRD de Montpellier, 911, avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5, France, Tel: (33) 4 67 41 64 41 – Fax: (33) 4 67 41 61 46 - E-mail: michel.boussinesq@ird.fr

Modelling Consortium

78. Dr Deirdre HOLLINGSWORTH, Assistant Professor in Epidemiology, Coordinator of the newly developed, Modelling Consortium, University of Warwick, United Kingdom, Tel: +44 24 7652 2698 – E-mail: deirdre.hollingsworth@warwick.ac.uk

RTI International/Task Force For Global Health

79. Dr Eric A. OTTESEN, MD, Director, ENVISION Program/Director, NTD Support Center, Washington DC, Decatur GA USA – Tel : 1-404-687-5604 – Email: eottesen@taskforce.org; eottesen@rti.org

80. Dr Njeri WAMAE, Consultant, KENYA Medical Research Institute, P.O. Box 54840-00200 – Email: gacheric.wamae@gmail.com

The Task Force for Global Health

81. Dr Patrick LAMMIE, Scientist, 325 Swanton Way, Decatur, GA 30030, United States – Tel: 1 404 687 5613 - Fax: 1 404 391 1138- E-mail: plammie@taskforce.org
WHO/HQ/GENEVA-OMS/SIEGE/GENEVE

82. Dr Dirk ENGELS, Coordinator PCT Unit, NTD Department, World Health Organization (WHO/HQ), 20 Avenue Appia, CH-1211, Geneva 27, Switzerland – Tel: +41 22 791 3824 – Fax: +41 22 791 4777 - Email: engelsd@who.int

83. Mr Xavier DANAY, Senior Legal Officer, Office of the Legal Counsel, World Health Organization (WHO/HQ), 20 Avenue Appia, CH-1211, Geneva 27, Switzerland – Tel: +41 22 791 1871 – Fax: +41 22 791 4158 – Email: daneyx@who.int

WHO-AFRO/OMS-AFRO

84. Dr Luis Gomes SAMBO, Regional Director, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: + 47 241 39386 ; 4 724 139 351 – E-mail: sambol@who.int

85. Dr Matshidiso Rebecca MOETI, Deputy Regional Director, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: + 47 241 39386 ; +263 11412857 – Fax: +47 241 39 506 - E-mail: moetim@who.int

86. Dr Francis KASOLO, Director, Disease Prevention and Control, World Health Organization Regional Office for Africa (WHO.AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: +24 06 508 11 01 – Fax: +47 241 39 503 - E-mail: kasolof@who.int

87. Dr Chris Ngenda MWIKISA, Chair of the CSA, TCC/Country Analysis & Support, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: 263 772161792 – Email: mwikisac@who.int

88. Dr Benido IMPOUMA, Programme Manager, Regional Adviser, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: +242 660 58 80 - E-mail: impoumab@who.int

89. Dr Adiele ONYEZE, Programme Manager, NTD, Medical Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: +47 241 39161; +263 4 788220-39 – E-mail: onyezea@who.int

90. Dr Yahaya ALI AHMED, Regional Adviser Medical Officer Epidemiologist, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Email: aliahmedy@who.int

91. Dr Jean-Marie DANGOU, Regional Adviser, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo - Email : dangouj@who.int

92. Dr Tieman DIARRA, Social Sicentist Community Based, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06 - Email: diarrati@who.int

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
21
93. Dr Issa SANOU, Research Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Email: sanoui@who.int

94. Mr Boniface Ekoue KINVI, Technical Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: +242 066908168 - Email: kinvie@who.int

95. Dr Simona MINCHIOTTI, Medical Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo - Email: minchiottis@who.int

96. Dr Sebastiana Dos A K T Da Gama NKOMO, Medical Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo - Email: nkamos@who.int

97. Dr Steven Velabo SHONGWE, Programme Manager NCD, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Email: shongwes@who.int

98. Dr Landry BIDE, Landry, Technical Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo, Email: bidel@who.int

99. Dr Alexandre TIENDREBEOGO, Monitoring & Evaluat Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Email: tiendrebeogoa@who.int

100. Mr Charlemagne PISSARA, Administrative Services Officer, World Health Organization, Regional Office for Africa (WHO/AFRO), Cité du Djoué, BP 06, Brazzaville, Congo – Tel: (242) 06 508 1096 - Email: pissarach@who.int;

101. Ms Gisèle Caroline NITCHEU HACHOM WABO, Manager, Regional Support Unit for DPC Cluster, WHO-AFRO, Tel: +47 241 39339 – Fax: +47 241 39100 - E-mail: nitcheug@who.int

102. Ms Marie Agnès NZENG-SENDZE, Administrateur du Budget et des Finances, Département de la Lutte Contre la Maladie, Programme Budget and Finance Officer, Diseases Prevention and Control Cluster, WHO/Regional Office for Africa, Office : (+47 241) 39652 - Mobile : (+242) 05 525 83 90 - Brazzaville (Congo) - E-mail: sendzea@who.int

WHO-CONGO/OMS-CONGO

103. Dr Fatoumata Binta T. DIALLO, Représentant de l’Organisation Mondiale de la Santé (OMS), B.P. 2465 Brazzaville, République du Congo – Tel : +242 663 83 29 ; +242 666 33 56 – Fax: +242 81 34 47 – E-mail: diallof@who.int
104. Dr Prosper MOTIKABERA, Director Prevention & Control, Organisation Mondiale de la Santé (OMS), B.P. 2465 Brazzaville, République du Congo - Tel: 06 66 69 507 - E-mail: motikabera@who.int

105. Dr Jean-Baptiste ROUNGOU, Director, APOC, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 22 77 - Fax: +226 50 34 28 75 - Email: roungouj@who.int

106. Dr Laurent YAMEOGO, Coordinator, Director’s Office, APOC, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 41 04 – Fax: +226 50 34 28 75 - Email: yameogol@who.int

107. Dr Grace FOBIL, Chief, Sustainable Drug Distribution Unit, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou, Burkina Faso – Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75, Email: fobig@who.int

108. Dr Afework Tekle HAILEMARIAM, Epidemiologist, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou, Burkina Faso - Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75, Email: teklea@who.int

109. Prof. Daniel BOAKYE, Entomologist, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou, Burkina Faso - Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75, Email: boakyed@who.int

110. Dr François SOBELA, Health System Specialist, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou, Burkina Faso - Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75, Email: sobelaf@who.int

111. Mr Honorat Gustave ZOURE, Responsible, Biostatistics and Mapping, APOC, Avenue Naaba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 29 59 – Fax: +226 50 34 28 75 - Email: zoureh@who.int

112. Mr Asmani BIZIMANA, Budget and Finance Officer, APOC, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 29 53 – Fax: (226) 50 34 28 75 - Email: bizimanaa@who.int

113. Mr Ibrahim TOURE, Administrative Officer, APOC, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 29 59 – Fax: +226 50 34 28 75 – Email: toureibr@who.int

114. Mr Yaovi AHOLOU, Programme Officer, Avenue Naba Zombré N° 1473, B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 59 53 – Fax: +226 50 34 28 75 - E-mail: aholouy@who.int

Nineteenth Session of the Joint Action Forum (JAF19), Brazzaville, December 2013
115. Dr Raogo Augustin KIMA, Translator, APOC, Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: +226 50 34 29 59 – Fax: +226 50 34 28 75 – Email: kimar@who.int

116. Mrs Marie Emilie ZOUGMORE, APOC Director's Assistant, Avenue Naba Zombré N° 1473, B.P. 549, Ouagadougou 01, Burkina Faso – Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75 - Email: zougmorem@who.int

117. Mrs Marie Rose KABORE, Administrative Assistant, Meetings, Avenue Naba Zombré N° 1473, B.P. 549, Ouagadougou 01, Burkina Faso – Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75 – Email: ouedraogor@who.int

APOC TECHNICAL CONSULTATIVE COMMITTEE

118. Prof. Mamoun HOMEIDA, P.O. Box 12810, Khartoum, Sudan – Tel: +249183227599 – Fax: +249183224799 – E-mail: amst33@hotmail.com

INTERPRETERS/INTERPRETES

119. Mr Christian STENERSEN, 123 Les Rossanets, F-01170 Segny (France)-Tel: +33 45041 7880 - Email: christian.stenersen@orange.fr

120. Ms Geneviève CLEMENT, Le Parc du Jura, 42 avenue du Jura, F-01210 Ferney-Voltaire, France - Tel: +33 456820578 – Email: g.clement@club-internet.fr

121. Mrs Safiétou BARRY, 09 B.P. 526 Ouagadougou 09, Burkina Faso - Tel: (+226) 50 37 74 14 82, Cellulaire (+226) 70 21 41 14 / 78 03 64 55 – Email: safia_barry@yahoo.fr; barrysafietou@gmail.com

122. Mr Victor IMBOUA-NIAVA, 16, Tantra Link North Kaneshie, Accra, Ghana – Res/Off: (233-30) 222 6911 - GSM: (233-27) 521 0790; (233-24) 4733 0068 – E-mail: vimbouaniava@yahoo.com; v.imboua-niava@aiic.net

123. Mrs Sofia REMEDIOS, Av. Das Acacias, 108, 2765-389 Monte Estoril, Portugal - Tel: 351 917787741 / 351 214681810 - E-mail: remedios39@gmail.com

124. Ms Maria TEIXEIRA, 1283 Prima Vista Estate, Dereham Drive, Mulbarton Ext. 2, ZA-2055, Johannesburg, South Africa – Email: maria@fast.co.za

125. Ms Maria Eduarda FORDHAM, Rua Dr Egas Moniz, 2-2D; Estoril, 2765-218, Lisbon, Portugal – Email: memfordham@gmail.com
126. Mrs. Kathryn Jane WATSON, Interpreter, Av. Infante D. Henrique 723, PT-2750-170 Cascais Lisbon, Portugal – Tel/Fax: +351-214 820 856 – Mobile: +351-962 337 668 – E-mail: kathrynwatson43@gmail.com

TRANSLATORS/TRADUCTEURS

127. Mr Emmanuel N. MENSAH, Translator/Reviser/Editor, P.O. Box CT 2106, Cantonments, Accra, Ghana – Tel: +233 244 560 521 – E-mail: wals123@yahoo.com

128. Ms. Lara Veronique PINTO, Interpreter & Translator, Flat 2, Hardwick House, 158 Psalter Lane, Sheffield – United Kingdom S11 8UR - Tel: + 44 114 268 5694 - Mobile: + 44 772 463 4661 - E-mail: lara.v.pinto@gmail.com

RAPPORTEURS

129. Professeur Soungalo TRAORE, Coordonnateur du Programme National de Lutte contre l’Onchocercose (PNLO), Ministère de la Santé, 03 BP 7009, Ouagadougou 03, Burkina Faso - Tel: +226 70 26 06 71 – E-mail: pefoungo@yahoo.fr

130. Mr Tom Luroni LAKWO, Senior Entomologist, National Coordinator, National Onchocerciasis Control Programme (NOCP) Secretariat, Ministry of Health, P.O. Box 7272, Kampala, Uganda – Tel: +256-414-348332 – Fax: +256-414-348339 - Email: tlakwo@gmail.com

131. Mr Chukwu OKORONKWO, National Onchocerciasis Control Programme (NOCP), Federal Ministry of Health, Federal Secretariat Phase III, P.O. Box 083, Garki, Maitama-Abuja, Nigeria – Tel: +234 80 33 61 98 94 – E-mail: chukwu@gmail.com; chukoro_christ@yahoo.co.uk

MEDIA/COMMUNICATION

132. Mrs Thérèse Régine BELOBO, Communication and Advocacy Officer (CAO/APOC), Avenue Naba Zombré N° 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso – Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75 – E-mail: belobot@oncho.afro.who.int

133. Mrs Zainab AKIWUMI, Freetown - Sierra Leone, Permanent address: 710 Fletcher Drive, Winder, Georgia 30680, USA - Tel: 1 678 343 1130 - Email: zainabaki@yahoo.co.uk

134. Mr Souleymane KONE, Health Information and Promotion Officer (HIP), World Health Organization, 01 BP 2494 Abidjan 01, Côte d’Ivoire – Tel: +225.22.51.72.00 – Fax: +225.22.51.72.32 – Cell: +225.07.14.83.93 – E-mail: kones@ci.afro.who.int

135. Mrs Antoinette Nana ILBOUDO, Secretary to Communication and Advocacy Officer, Sustainable Drug Distribution Unit (CAO/APOC), P.O. Box 549, Ouagadougou 01, Burkina Faso – Tel: +226 50 34 29 53 – Fax: +226 50 34 28 75 – E-mail: nanaa@oncho.afrowho.int
CONSULTANTS

136. Mrs Catherine HODGKIN, Consultant, Linnaeusparkweg 35, 1098 CP, Amsterdam, Netherlands, Tel: +0031 206 651 413 – Mobile: +0031 623 939 602 – E-mail: chodgkin@s4all.nl; Catherine.Hodgkin@gmail.com

137. Dr Ricardo THOMPSON, Senior Researcher Scientist, National Institute of Health, Av. Eduardo Mondlane, 1008, Maputo, P.O. Box 264, Maputo, Republic of Mozambique – Tel: +258 823 060 036 – E-mail: rthompsonmz@gmail.com

138. Dr Nana-Kwadwo BIRITWUM, Programme Manager, Neglected Tropical Diseases Programme (NTD), Ghana Health Service, P.O. Box MB-190, Accra – Ghana – Tel: +233 208 232 286 – Fax: +233 302 226 739 – E-mail: nanakwadwo.biritwum@ghsmai.org; nkadbiritwum@gmail.com

139. Prof. Kodjo EVLO, Université de Lomé, B.P. 3237, Lome, Togo - Tel: +228-226-8614, or +228-901-5958 - E-mail: koevlo@tg.refer.org; kodjo.evlo@yahoo.com

140. Dr Kofi AMPONSAH, Corbin Ct., Woodbridge, VA 22191, United States – Tel: (703) 459-0504 kofiamponsah@hotmail.com